Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report.

ABSTRACT: HER2-positive acantholytic squamous cell carcinoma (ASCC) of the breast is exceptionally rare, and its clinicopathologic features are poorly understood. The impact of neoadjuvant therapy on HER2-positive breast ASCC is unclear. Here we report on a 58-year-old woman who was diagnosed with HER2-positive ASCC of the right breast, who underwent neoadjuvant treatment with albumin-paclitaxel, carboplatin, and trastuzumab, and surgery. Neoadjuvant therapy was effective, with no recurrence or metastasis after 1.5 years of postoperative follow-up.

SUBMITTER: Cong J 

PROVIDER: S-EPMC10566270 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature